LSV Asset Management Cuts Stake in Jazz Pharmaceuticals PLC $JAZZ

LSV Asset Management cut its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 1.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 2,511,858 shares of the specialty pharmaceutical company’s stock after selling 41,884 shares during the period. LSV Asset Management’s holdings in Jazz Pharmaceuticals were worth $331,063,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Vestal Point Capital LP bought a new stake in shares of Jazz Pharmaceuticals during the second quarter valued at approximately $127,344,000. AQR Capital Management LLC boosted its stake in Jazz Pharmaceuticals by 62.1% during the 2nd quarter. AQR Capital Management LLC now owns 794,770 shares of the specialty pharmaceutical company’s stock valued at $84,341,000 after purchasing an additional 304,463 shares during the last quarter. Allianz Asset Management GmbH increased its holdings in shares of Jazz Pharmaceuticals by 453.9% in the 2nd quarter. Allianz Asset Management GmbH now owns 325,403 shares of the specialty pharmaceutical company’s stock worth $34,532,000 after purchasing an additional 266,658 shares in the last quarter. Boston Trust Walden Corp raised its stake in shares of Jazz Pharmaceuticals by 129.1% in the second quarter. Boston Trust Walden Corp now owns 407,897 shares of the specialty pharmaceutical company’s stock worth $43,286,000 after purchasing an additional 229,885 shares during the last quarter. Finally, Wedge Capital Management L L P NC bought a new position in shares of Jazz Pharmaceuticals during the third quarter valued at $27,834,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insider Activity

In other news, Director Bruce C. Cozadd sold 77,500 shares of the business’s stock in a transaction dated Wednesday, November 26th. The stock was sold at an average price of $177.81, for a total value of $13,780,275.00. Following the transaction, the director directly owned 393,332 shares in the company, valued at $69,938,362.92. The trade was a 16.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Mary Elizabeth Henderson sold 2,238 shares of the stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $169.51, for a total value of $379,363.38. Following the sale, the senior vice president owned 19,508 shares of the company’s stock, valued at $3,306,801.08. This represents a 10.29% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 123,791 shares of company stock worth $21,991,850. 4.30% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Trading Up 0.4%

Shares of NASDAQ:JAZZ opened at $166.24 on Thursday. The stock has a 50 day moving average of $167.68 and a 200 day moving average of $146.52. The company has a market cap of $10.10 billion, a PE ratio of -27.39, a price-to-earnings-growth ratio of 0.89 and a beta of 0.26. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $182.99. The company has a current ratio of 1.65, a quick ratio of 1.44 and a debt-to-equity ratio of 1.09.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on JAZZ. Piper Sandler reissued an “overweight” rating and issued a $219.00 target price (up previously from $147.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, December 10th. Needham & Company LLC increased their price objective on shares of Jazz Pharmaceuticals from $210.00 to $235.00 and gave the company a “buy” rating in a research report on Monday, January 12th. Bank of America lifted their target price on shares of Jazz Pharmaceuticals from $230.00 to $247.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. TD Cowen reiterated a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Thursday, January 29th. Finally, Morgan Stanley restated an “overweight” rating and issued a $225.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, January 8th. Fourteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $205.67.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.